Abstract: An apparatus 100 for sensing a physiological parameter of a subject comprises a force sensor 102 configured to generate a first signal representing force displacement of an organ of the subject and a displacement sensor 104 associated with the force sensor 102. The displacement sensor 104 is configured to generate a second signal representing displacement velocity of the organ of the subject. A coupler 106 is arranged on one of the force sensor 102 and the displacement sensor 104, the coupler 106 being configured to mechanically couple the force sensor 102 and the displacement sensor 104 with the organ.

Abstract: A blood volume monitor includes a carrier mountable on a subject's body part. A measuring arrangement is mounted on the carrier. The measuring arrangement provides data relating to a change in volume of the body part, and outputs signals representative of the change. A control unit is in communication with the measuring arrangement to process data output by the measuring arrangement to determine, using the volume data, the volume of the body part and determines blood volume in the body part. The control unit uses the response signals received from the measuring arrangement and the determined volume of the part of the body to determine the blood volume.

Abstract: The invention relates to methods for generating cell-type specific expression cassettes and reporter vectors, as well as nucleic acid constructs that can be generated by such methods. The cell-type specific expression cassettes and reporter vectors are characterized synthetic cis-regulatory DNA, also termed synthetic locus regions (sLCRs). sLCRs allow for a cell-type specific expression of reporter or effector genes. The invention further relates to various uses of the reporter vectors, including the determination of a property of a cell, preferably a cell type, state or fate transition, in gene and viral therapy, drug discovery or validation.

Abstract: A pneumocardial function monitor includes a carrier configured to be mounted about at least a part of a trunk of a body of a subject. A sensing arrangement is mounted on the carrier, the sensing arrangement including at least one element for monitoring changes in volume of the part of the subject's body. A signal processing module is in communication with the sensing arrangement for processing signals output from the sensing arrangement, the signal processing module having at least one output for outputting a signal related to respiratory function and/or cardiac function.

Abstract: A pneumocardial function monitor includes a carrier configured to be mounted about at least a part of a trunk of a body of a subject. A sensing arrangement is mounted on the carrier, the sensing arrangement including at least one element for monitoring changes in volume of the part of the subject's body. A signal processing module is in communication with the sensing arrangement for processing signals output from the sensing arrangement, the signal processing module having at least one output for outputting a signal related to respiratory function and/or cardiac function.

Abstract: A blood volume monitor includes a carrier mountable on a subject's body part. A measuring arrangement is mounted on the carrier. The measuring arrangement provides data relating to a change in volume of the body part, and outputs signals representative of the change. A control unit is in communication with the measuring arrangement to process data output by the measuring arrangement to determine, using the volume data, the volume of the body part and determines blood volume in the body part. The control unit uses the response signals received from the measuring arrangement and the determined volume of the part of the body to determine the blood volume.

Abstract: A pregnancy test system (10) includes a carrier (14) carrying a plurality of (sensors 12) arranged in a fixed relationship relative to one another. A signal processing (circuit 42) processes data sensed by the sensors (12) and outputs a data signal representative of the pregnancy status of an animal being examined. A support arrangement (24) supports the carrier (14) in a desired position relative to the animal. A positioning mechanism (26) is associated with the carrier (14) for positioning the carrier (14) at the desired position relative to the animal.

Abstract: Equipment (10) for non-invasively measuring a physiological process includes at least one receiver (12) to be placed relative to a body of a subject being examined to detect at least one signal from the body of the subject. A discrimination unit (20.1) determines if the at least one signal is a signal of interest associated with the physiological process. A processor (20) processes the signal of interest to enhance the signal of interest and suppresses other received signals that are not of interest.

Abstract: A pregnancy test system (10) includes a carrier (14) carrying a plurality of (sensors 12) arranged in a fixed relationship relative to one another. A signal processing (circuit 42) processes data sensed by the sensors (12) and outputs a data signal representative of the pregnancy status of an animal being examined. A support arrangement (24) supports the carrier (14) in a desired position relative to the animal. A positioning mechanism (26) is associated with the carrier (14) for positioning the carrier (14) at the desired position relative to the animal.

Abstract: New histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH2, CH—NR3R4, NR5 or oxygen, X is CH or nitrogen, Y is a bond, CH2, oxygen or NR6, Z is CH or nitrogen, R1, R2 are, independently, hydrogen, halogen, C1-C6 alkyl or C1-C6 haloalkyl, R11, R12 are, independently, hydrogen or C1-C6 alkyl, and R3, R4, R5 and R6 are as further defined in the specification.

Abstract: This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH2, NR5 or oxygen, X is CH or nitrogen, Y is a bond, CH2, oxygen or NR6, Z is CH or nitrogen, R1, R2 are, independently, hydrogen or C1-C6 alkyl, R3, R4 are, independently, hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1-C6 haloalkoxy, and R5 and R6 are as further defined in the specification, and pharmaceutical acceptable salts thereof.

Abstract: Equipment (10) for non-invasively measuring a physiological process includes at least one receiver (12) to be placed relative to a body of a subject being examined to detect at least one signal from the body of the subject. A discrimination unit (20.1) determines if the at least one signal is a signal of interest associated with the physiological process. A processor (20) processes the signal of interest to enhance the signal of interest and suppresses other received signals that are not of interest.

Abstract: New inhibitors of histone deacetylases having antitumor activity, and the process of preparation thereof are herein described. These compounds belong to the structural formula (I) where R1 is a linear or branched chain containing at least two conjugated double bonds, A is an optionally substituted phenyl or pyridyl ring, Ar is an aryl or heteroaryl group, and R3 is hydrogen or alkoxyalkyl. The application also describes the use of said compounds in the treatment of diseases associated to the deregulation of histone deacetylases activity, such as tumors, as well as the relevant pharmaceutical compositions for administration to patients requiring said treatment.

Abstract: A system (10) for sensing electrophysiological signals includes a plurality of shielded electrodes (12). The electrodes (12) are connected to an amplifier (18) for amplifying signals received from each of the electrodes (12), the amplifier having a shielding input and the shielding of the electrodes (12) being connected to the shielded input of the amplifier (18). A power supply (22) powers the amplifier (18), a reference voltage derived from the power supply (22) being used as a reference voltage for the electrodes (12).

Abstract: New histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH2, CH—NR3R4, NR5 or oxygen, X is CH or nitrogen, Y is a bond, CH2, oxygen or NR6, Z is CH or nitrogen, R1, R2 are, independently, hydrogen, halogen, C1-C6 alkyl or C1-C6 haloalkyl, R11, R12 are, independently, hydrogen or C1-C6 alkyl, and R3, R4, R5 and R6 are as further defined in the specification.

Abstract: New inhibitors of histone deacetylases having antitumor activity, and the process of preparation thereof are herein described. These compounds belong to the structural formula (I) where R1 is a linear or branched chain containing at least two conjugated double bonds, A is an optionally substituted phenyl or pyridyl ring, Ar is an aryl or heteroaryl group, and R3 is hydrogen or alkoxyalkyl. The application also describes the use of said compounds in the treatment of diseases associated to the deregulation of histone deacetylases activity, such as tumors, as well as the relevant pharmaceutical compositions for administration to patients requiring said treatment.

Abstract: New inhibitors of histone deacetylases having antitumor activity, and the process of preparation thereof are herein described. These compounds belong to the structural formula (I) where R1 is a linear or branched chain containing at least two conjugated double bonds, A is an optionally substituted phenyl or pyridyl ring, Ar is an aryl or heteroaryl group, and R3 is hydrogen or alkoxyalkyl. The application also describes the use of said compounds in the treatment of diseases associated to the deregulation of histone deacetylases activity, such as tumors, as well as the relevant pharmaceutical compositions for administration to patients requiring said treatment.

Abstract: New inhibitors of histone deacetylases having antitumor activity, and the process of preparation thereof are herein described. These compounds belong to the structural formula (I) where R1 is a linear or branched chain containing at least two conjugated double bonds, A is an optionally substituted phenyl or pyridyl ring, Ar is an aryl or heteroaryl group, and R3 is hydrogen or alkoxyalkyl. The application also describes the use of said compounds in the treatment of diseases associated to the deregulation of histone deacetylases activity, such as tumors, as well as the relevant pharmaceutical compositions for administration to patients requiring said treatment.